GlassScriptPhysician profile
William J Ravert
NPI 1093276289
$569.65
in general payments reported to CMS, 2019-2025
10 companies · $46.02 in 2025
The $46.02 reported for 2025 was less than what a typical Critical Care Medicine (Nurse Practitioner) provider received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.28 · 2022: $41.44 · 2023: $103 · 2024: $351 · 2025: $46.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $299 · Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $299.03 |
| Food and Beverage | $201.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $302.67 | 2024 | Venaseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.71 | 2021-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $39.53 | 2023-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $32.21 | 2022-2023 | |
| Verona Pharma, INC. | $31.97 | 2025 | Ohtuvayre |
| Biotronik INC. | $27.88 | 2023 | Biomonitor |
| Esperion Therapeutics, INC. | $23.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.67 | 2023 | |
| Abbvie INC. | $14.82 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $14.05 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ravert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.